We read with interest the guidelines on the clinical evaluation of the etiology of autism spectrum disorders by Schaefer et al. 1 Although we congratulate the authors on the development of these guidelines, we question the need for routine studies for chromosome anomalies and fragile X syndrome for patients with Asperger syndrome (AspS). The authors state that the generally reported rate of success for identifying a specific diagnosis for evaluations of patients with various categories of autism spectrum disorders including AspS is 6 -15%. The authors cite three references in support of this. The study by Abdul-Rahman and Hudgins 2 reported on 101 patients including 63 with pervasive developmental delay (PDD)/autism, 7 with AspS, 7 with autistic features, 20 with developmental delay/mental retardation, and 4 with other conditions. None of the patients with AspS had an underlying genetic diagnosis identified. Battaglia and Carey 3 described 65 patients with autism, 18 with PDD-not otherwise specified, and 2 with AspS. An etiologic diagnosis was made for nine of these patients. The report does not say if either of the AspS patients had an underlying diagnosis. Schaefer and Lutz 4 recommend an evaluation protocol for children with AspS or PDD yet their study reports on 32 patients with autism. None were reported to have AspS. They did however refer to six other studies in the development of their recommendations. One of the studies cited was the Battaglia and Carey 3 study described above. The other studies (Refs. 5-9) were reviewed. Challman et al. 5 collected data on five AspS patients but did not report those results. According to our review, we are not aware of any patients with AspS in those studies identified with a chromosome anomaly or fragile X syndrome.
To determine if AspS patients have been reported with a chromosome anomaly, we did a Medline search (as of July 2008), for "Asperger* Chromosome," "Asperger* Chromosomal," and "Asperger fragile X." The following cases reports were identified. Robertson et al. 10 reported on a woman with Gilles de la Tourette syndrome who had developmental delays and some features of AspS or autism spectrum disorder. She had a 22q11.2 deletion. Fontenelle et al. 11 reported a patient with AspS, obsessive-compulsive disorder, major depression, and 45,X/46,XY mosaicism. Tentler et al. 12 described two AspS patients with balanced translocations [t(13;17)(q14;p13) and t(17;19)(p13.3;cen)]. Their second patient was previously described by Annerén et al. 13 Saliba and Griffiths 14 found an inherited fragile site on chromosome 2 in a patient with AspS. We found several other studies [15] [16] [17] [18] [19] [20] [21] [22] [23] that evaluated a series of patients with autism spectrum disorders including AspS where fragile X testing and/or chromosome studies were done on all or part of the group. These studies are summarized in the Table. We also checked the Autism Chromosome Rearrangement Database. 24 There were two additional unbalanced karyotypes found in AspS patients. One unpublished case with possible AspS with growth delay and dysmorphic features had a 47,XY,ϩmar/46,XY karyotype. The marker was identified as der(7)(q11.1q11.23). Another patient described by Akefeldt and Gillberg 25 had atypical autism/AspS in addition to hypomelanosis of Ito had various clonal chromosomal abnormalities. In our own laboratory, we have done chromosome studies on 24 patients whose diagnosis was stated to be AspS. All had normal karyotypes. Nineteen of these patients had fragile X molecular testing. None had fragile X syndrome. One female patient was a premutation carrier (55 CGG repeats). One male patient had 51 CGG repeats which is considered in the gray zone.
COMMENT
Most of the chromosome anomalies described are likely coincidental rather than causative, and most are considered to be normal variants that would normally not be associated with any phenotypic effects, e.g., long Y; fragile sites; single cell low grade mosaicism (query cultural artifact). The anomalies that may be clinically significant are the XYY, the 45,X mosaic and the "major abnormality of 5p," the 22q deletion and the mosaic derivative 7. The first two are unlikely etiologically causative of AspS, but comorbid conditions. It is difficult to comment on the significance the 5p abnormality without further details. The patient with 22q deletion had more complex problems including intellectual deficiency that would normally warrant further genetic investigations. The patient with a mosaic derivative 7 chromosome also had additional features. The chromosome anomalies seen in the patient with hypomelanosis of Ito likely relate to that diagnosis rather than the AspS. 26 Our finding of one fragile X female carrier and one male with 51 CGG repeats is interesting. Farzin et al. 27 did report a higher frequency of autism spectrum disorders in fragile X premutation carriers although none were diagnosed with AspS. More research in the area is needed before testing for a fragile X premutation becomes a standard of practice for AspS.
One limitation of a literature review is that the diagnostic criteria for AspS used in the studies vary and have changed with time. Kopra et al. 28 described four diagnostic criteria for AspS, i.e., International Classification of Disease-10, Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition, the Gillberg & Gillberg, and the Szatmari criteria. The International Classification of Disease-10 criteria require lack of clinically significant delay in language or cognitive development in childhood. The Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition criteria state that there must be no clinically significant delay in cognitive development in childhood. The other two criteria sets do not specifically require a normal IQ.
Based on our review of the literature and our own experience we recommend a detailed history and physical examination of patients with AspS. If there are dysmorphic features, intellectual impairment, or other concerns, including a family history to suggest an X-linked disorder, further investigations such as chromosome analysis, array CGH, fragile X testing, and possibly other genetic studies associated with X-linked mental retardation is recommended. In our opinion, routine genetic investigations in uncomplicated AspS, in the absence of any of the above findings, is not recommended. However, this group of individuals may be useful for research using genetic markers to identify genes that lead to susceptibility to autism spectrum disorders. In a recent article summarizing two multidisciplinary workshops focused on reproductive counseling for FMR1 premutation carriers, Wittenberger et al. 5 defined the four allelic forms of FMR1 with respect to CGG repeat size. They stated that consensus has been reached, both in the literature and in the workshops regarding the size of the premutation at 55-200 repeats, and the full mutation at Ͼ200 repeats and these ranges agree with those in the Technical Standards and Guidelines as summarized in Table 1 . Wittenberger et al. also stated that consensus has not yet been reached for the lower limit of the intermediate or gray zone (i.e., 45-54 repeats or 40 -54 repeats).
The clinical significance of intermediate and low premutation size alleles is 3-fold. First, it is the extent to which they may be prone to instability, particularly expansion, in future generations. At the present time, the smallest repeat known to expand to a full mutation in one generation is 59 CGGs. 6, 7 Recognizing this and the fact that there is variation between laboratories and between laboratory methods when determining the exact CGG repeat number, the Laboratory Technical Standards and Guidelines place the boundaries of the premutation range at 55 and 200 CGG repeats. Quality Assurance challenges through the College of American Pathologists have shown that repeat lengths sized using polymerase chain reaction-based techniques can vary by Ϯ3-4 repeats. The Technical Standards and Guidelines allowed for this variation in choosing 55 repeats as the lower limit of the premutation range to avoid missing any women at risk for having a child with the Fragile X syndrome.
Second, the clinical significance is the extent to which these repeat size alleles increase the risk for premutation-associated Fragile X tremor ataxia syndrome (FXTAS). FXTAS is a lateonset neurodegenerative disorder with predominant features of cerebellar ataxia and intention tremor. Onset is usually in persons older than 50 years. The risk and/or severity of the disorder is associated with repeat size, the highest risk being associated with larger repeats. Among individuals with lateonset cerebellar ataxia, the prevalence of premutation alleles was 13 times greater than expected based on its prevalence in the general population as assessed by a recent meta-analysis. 8 Lastly, the clinical significance of intermediate/low premutation repeat size alleles is the extent to which they impose a risk for premutation-associated ovarian insufficiency. The prevalence of premature ovarian failure (POF) or cessation of menses before 40 years of age is about 20%, although it is highly associated with repeat size: the risk seems to increase with increasing premutation repeat size between 59 and 99, thereafter the risk of POF plateaus or even decreases for women with repeat sizes over 100. 9 Premutation carriers have been identified in about 3% of women with sporadic POF and in about 12% of women with familial POF. 10 Thus, at this point, the risk and/or severity of all three disorders associated with premutation alleles (i.e., instability during transmission, FXTAS and POF) is established for alleles 55-200 repeats. The risk among the alleles in the lower part of this range, 55-70 is significantly lower than that in the upper range, 70 -200, for all three disorders. Table 2 shows the distribution of repeats among the allelic forms of FMR1 between 41 repeats and 200 repeats as defined in the two conflicting ACMG publications. The table demonstrates that, were genetic counseling to be based on the Practice Full mutation Ͼ200 Ͼ200 Ͼ200 Ͼ200 2 The ACMG Quality Assurance Committee and the Professional Practice and Guidelines Committee recommend that the following ranges for CGG repeat size be used in the laboratory as well as in clinical practice:
